+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generics BRIC (Brazil, Russia, India, China) Industry Guide 2014-2023

  • ID: 5004263
  • Report
  • February 2020
  • Region: China, India, Brazil, Russia
  • 126 pages
  • MarketLine
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma Ltd
  • Cipla Limited
  • EMS SA
  • Eurofarma Laboratorios SA
  • Krka, d. d., Novo mesto
  • MORE
Generics BRIC (Brazil, Russia, India, China) Industry Guide 2014-2023

Summary

The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the BRIC generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights
  • Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $96,980.0 million in 2018. Russia was the fastest growing country with a CAGR of 12.7% over the 2014-18 period.
  • Within the generics industry, China is the leading country among the BRIC nations with market revenues of $66,912.9 million in 2018. This was followed by India, Russia and Brazil with a value of $15,415.2, $8,466.0, and $6,185.9 million, respectively.
  • China is expected to lead the generics industry in the BRIC nations with a value of $85,292.3 million in 2023, followed by India, Russia, Brazil with expected values of $23,288.6, $13,541.6 and $8,217.1 million, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
  • Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
  • Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to buy
  • What was the size of the BRIC generics market by value in 2018?
  • What will be the size of the BRIC generics market in 2023?
  • What factors are affecting the strength of competition in the BRIC generics market?
  • How has the market performed over the last five years?
  • How large is the BRIC generics market in relation to its regional counterparts?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Aurobindo Pharma Ltd
  • Cipla Limited
  • EMS SA
  • Eurofarma Laboratorios SA
  • Krka, d. d., Novo mesto
  • MORE
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 BRIC Generics
2.1. Industry Outlook

3 Generics in Brazil
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators
3.7. Country data

4 Generics in China
4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis
4.6. Macroeconomic Indicators
4.7. Country data

5 Generics in India
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators
5.7. Country data

6 Generics in Russia
6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators
6.7. Country data

7 Company Profiles
7.1. Sanofi SA
7.2. EMS SA
7.3. Ache Laboratorios Farmaceuticos SA
7.4. Eurofarma Laboratorios SA
7.5. Teva Pharmaceutical Industries Limited
7.6. Mylan N.V.
7.7. China Grand Pharmaceutical and Healthcare Holdings Limited
7.8. Pfizer Inc.
7.9. Sun Pharmaceutical Industries Ltd
7.10. Lupin Ltd
7.11. Aurobindo Pharma Ltd
7.12. Cipla Limited
7.13. Krka, d. d., Novo mesto
7.14. Abbott Laboratories

Appendix

List of Tables
Table 1: BRIC Generics industry, revenue($m), 2014-23
Table 2: BRIC Generics industry, revenue($m), 2014-18
Table 3: BRIC Generics industry, revenue($m), 2018-23
Table 4: Brazil generics market value: $ million, 2014-18
Table 5: Brazil generics market volume: % of total pharma, 2014-18
Table 6: Brazil generics market geography segmentation: $ million, 2018
Table 7: Brazil generics market value forecast: $ million, 2018-23
Table 8: Brazil generics market volume forecast: % of total pharma, 2018-23
Table 9: Brazil size of population (million), 2014-18
Table 10: Brazil gdp (constant 2005 prices, $ billion), 2014-18
Table 11: Brazil gdp (current prices, $ billion), 2014-18
Table 12: Brazil inflation, 2014-18
Table 13: Brazil consumer price index (absolute), 2014-18
Table 14: Brazil exchange rate, 2014-18
Table 15: China generics market value: $ million, 2014-18
Table 16: China generics market volume: % of total pharma, 2014-18
Table 17: China generics market geography segmentation: $ million, 2018
Table 18: China generics market value forecast: $ million, 2018-23
Table 19: China generics market volume forecast: % of total pharma, 2018-23
Table 20: China size of population (million), 2014-18
Table 21: China gdp (constant 2005 prices, $ billion), 2014-18
Table 22: China gdp (current prices, $ billion), 2014-18
Table 23: China inflation, 2014-18
Table 24: China consumer price index (absolute), 2014-18
Table 25: China exchange rate, 2014-18
Table 26: India generics market value: $ million, 2014-18
Table 27: India generics market volume: % of total pharma, 2014-18
Table 28: India generics market geography segmentation: $ million, 2018
Table 29: India generics market value forecast: $ million, 2018-23
Table 30: India generics market volume forecast: % of total pharma, 2018-23
Table 31: India size of population (million), 2014-18
Table 32: India gdp (constant 2005 prices, $ billion), 2014-18
Table 33: India gdp (current prices, $ billion), 2014-18
Table 34: India inflation, 2014-18
Table 35: India consumer price index (absolute), 2014-18
Table 36: India exchange rate, 2014-18
Table 37: Russia generics market value: $ million, 2014-18
Table 38: Russia generics market volume: % of total pharma, 2014-18
Table 39: Russia generics market geography segmentation: $ million, 2018
Table 40: Russia generics market value forecast: $ million, 2018-23
Table 41: Russia generics market volume forecast: % of total pharma, 2018-23
Table 42: Russia size of population (million), 2014-18
Table 43: Russia gdp (constant 2005 prices, $ billion), 2014-18
Table 44: Russia gdp (current prices, $ billion), 2014-18
Table 45: Russia inflation, 2014-18
Table 46: Russia consumer price index (absolute), 2014-18
Table 47: Russia exchange rate, 2014-18
Table 48: Sanofi SA: key facts
Table 49: Sanofi SA: Annual Financial Ratios
Table 50: Sanofi SA: Key Employees
Table 51: Sanofi SA: Key Employees Continued
Table 52: EMS SA: key facts
Table 53: EMS SA: Key Employees
Table 54: Ache Laboratorios Farmaceuticos SA: key facts
Table 55: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 56: Eurofarma Laboratorios SA: key facts
Table 57: Eurofarma Laboratorios SA: Key Employees
Table 58: Teva Pharmaceutical Industries Limited: key facts
Table 59: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 60: Teva Pharmaceutical Industries Limited: Key Employees

List of Figures
Figure 1: BRIC Generics industry, revenue($m), 2014-23
Figure 2: BRIC Generics industry, revenue($m), 2014-18
Figure 3: BRIC Generics industry, revenue($m), 2018-23
Figure 4: Brazil generics market value: $ million, 2014-18
Figure 5: Brazil generics market volume: % of total pharma, 2014-18
Figure 6: Brazil generics market geography segmentation: % share, by value, 2018
Figure 7: Brazil generics market value forecast: $ million, 2018-23
Figure 8: Brazil generics market volume forecast: % of total pharma, 2018-23
Figure 9: Forces driving competition in the generics market in Brazil, 2018
Figure 10: Drivers of buyer power in the generics market in Brazil, 2018
Figure 11: Drivers of supplier power in the generics market in Brazil, 2018
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2018
Figure 13: Factors influencing the threat of substitutes in the generics market in Brazil, 2018
Figure 14: Drivers of degree of rivalry in the generics market in Brazil, 2018
Figure 15: China generics market value: $ million, 2014-18
Figure 16: China generics market volume: % of total pharma, 2014-18
Figure 17: China generics market geography segmentation: % share, by value, 2018
Figure 18: China generics market value forecast: $ million, 2018-23
Figure 19: China generics market volume forecast: % of total pharma, 2018-23
Figure 20: Forces driving competition in the generics market in China, 2018
Figure 21: Drivers of buyer power in the generics market in China, 2018
Figure 22: Drivers of supplier power in the generics market in China, 2018
Figure 23: Factors influencing the likelihood of new entrants in the generics market in China, 2018
Figure 24: Factors influencing the threat of substitutes in the generics market in China, 2018
Figure 25: Drivers of degree of rivalry in the generics market in China, 2018
Figure 26: India generics market value: $ million, 2014-18
Figure 27: India generics market volume: % of total pharma, 2014-18
Figure 28: India generics market geography segmentation: % share, by value, 2018
Figure 29: India generics market value forecast: $ million, 2018-23
Figure 30: India generics market volume forecast: % of total pharma, 2018-23
Figure 31: Forces driving competition in the generics market in India, 2018
Figure 32: Drivers of buyer power in the generics market in India, 2018
Figure 33: Drivers of supplier power in the generics market in India, 2018
Figure 34: Factors influencing the likelihood of new entrants in the generics market in India, 2018
Figure 35: Factors influencing the threat of substitutes in the generics market in India, 2018
Figure 36: Drivers of degree of rivalry in the generics market in India, 2018
Figure 37: Russia generics market value: $ million, 2014-18
Figure 38: Russia generics market volume: % of total pharma, 2014-18
Figure 39: Russia generics market geography segmentation: % share, by value, 2018
Figure 40: Russia generics market value forecast: $ million, 2018-23
Figure 41: Russia generics market volume forecast: % of total pharma, 2018-23
Figure 42: Forces driving competition in the generics market in Russia, 2018
Figure 43: Drivers of buyer power in the generics market in Russia, 2018
Figure 44: Drivers of supplier power in the generics market in Russia, 2018
Figure 45: Factors influencing the likelihood of new entrants in the generics market in Russia, 2018
Figure 46: Factors influencing the threat of substitutes in the generics market in Russia, 2018
Figure 47: Drivers of degree of rivalry in the generics market in Russia, 2018
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Sanofi SA
  • EMS SA
  • Ache Laboratorios Farmaceuticos SA
  • Eurofarma Laboratorios SA
  • Teva Pharmaceutical Industries Limited
  • Mylan N.V.
  • China Grand Pharmaceutical and Healthcare Holdings Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Lupin Ltd
  • Aurobindo Pharma Ltd
  • Cipla Limited
  • Krka, d. d., Novo mesto
  • Abbott Laboratories
Note: Product cover images may vary from those shown
Adroll
adroll